Egetis Therapeutics Valuation
| EGTX Stock | SEK 5.40 0.01 0.18% |
At this time, the firm appears to be overvalued. Egetis Therapeutics shows a prevailing Real Value of kr5.03 per share. The current price of the firm is kr5.4. Our model computes the value of Egetis Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 52.07 %, operating margin of (7.54) %, and Shares Outstanding of 249.59 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Egetis Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Egetis Therapeutics is based on 3 months time horizon. Increasing Egetis Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Egetis Therapeutics' intrinsic value may or may not be the same as its current market price of 5.40, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.4 | Real 5.03 | Hype 5.4 | Naive 5.27 |
The intrinsic value of Egetis Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Egetis Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Egetis Therapeutics AB helps investors to forecast how Egetis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Egetis Therapeutics more accurately as focusing exclusively on Egetis Therapeutics' fundamentals will not take into account other important factors: Egetis Therapeutics Total Value Analysis
Egetis Therapeutics AB is currently anticipated to have takeover price of 698.73 M with market capitalization of 1.51 B, debt of 4.88 M, and cash on hands of 207.41 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Egetis Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
698.73 M | 1.51 B | 4.88 M | 207.41 M |
Egetis Therapeutics Investor Information
About 52.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.52. Some equities with similar Price to Book (P/B) outperform the market in the long run. Egetis Therapeutics recorded a loss per share of 0.7. The entity had not issued any dividends in recent years. Based on the key indicators related to Egetis Therapeutics' liquidity, profitability, solvency, and operating efficiency, Egetis Therapeutics AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Egetis Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Egetis Therapeutics has an asset utilization ratio of 6.72 percent. This implies that the Company is making kr0.0672 for each dollar of assets. An increasing asset utilization means that Egetis Therapeutics AB is more efficient with each dollar of assets it utilizes for everyday operations.Egetis Therapeutics Ownership Allocation
Egetis Therapeutics holds a total of 249.59 Million outstanding shares. Egetis Therapeutics AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Egetis Therapeutics Profitability Analysis
The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M).About Egetis Therapeutics Valuation
The stock valuation mechanism determines Egetis Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Egetis Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Egetis Therapeutics. We calculate exposure to Egetis Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Egetis Therapeutics's related companies.Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
8 Steps to conduct Egetis Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Egetis Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Egetis Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Egetis Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Egetis Therapeutics' revenue streams: Identify Egetis Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Egetis Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Egetis Therapeutics' growth potential: Evaluate Egetis Therapeutics' management, business model, and growth potential.
- Determine Egetis Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Egetis Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.